The estimated Net Worth of Christopher G White is at least $1.71 Milhão dollars as of 3 February 2024. Mr. White owns over 5,910 units of Ocular Therapeutix Inc stock worth over $1,043,935 and over the last 13 years he sold OCUL stock worth over $668,737. In addition, he makes $0 as Senior Vice President e Head of Business and Corporate Development at Ocular Therapeutix Inc.
Christopher has made over 10 trades of the Ocular Therapeutix Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 5,910 units of OCUL stock worth $28,723 on 3 February 2024.
The largest trade he's ever made was selling 10,000 units of Ocular Therapeutix Inc stock on 7 January 2013 worth over $159,300. On average, Christopher trades about 2,465 units every 220 days since 2012. As of 3 February 2024 he still owns at least 123,689 units of Ocular Therapeutix Inc stock.
You can see the complete history of Mr. White stock trades at the bottom of the page.
Christopher G. White serves as Senior Vice President, Head of Business and Corporate Development of the Company. He brings over 25 years of operations management, business development, partnering and strategic planning experience in the biopharmaceutical industry. Prior to joining Ocular, Mr. White was the Chief Operating Officer at Silver Creek Pharmaceuticals, a private Bay Area biotechnology company focused on the development of novel regenerative medicines. Prior to his work at Silver Creek, Mr. White held senior leadership positions in the biotechnology industry, including Chief Business Officer at both Entasis Therapeutics and AMAG Pharmaceuticals, where he was responsible for business and corporate development, portfolio management, and strategic planning. Prior to entering the biotechnology industry, Mr. White worked as a partner at management consulting firms Accenture and A.T. Kearney, where he advised pharmaceutical and biopharmaceutical clients on a broad range of commercial and strategic issues. Mr. White holds a Bachelor of Science degree in Chemical Engineering from Tufts University and a Master of Business Administration from Columbia University.
Christopher's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 24 CROSBY DRIVE, BEDFORD, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer, eVenture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: